ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes Awarded $2.5M From NIH to Study Sepsis Drug Targets

Sepsis affects at least 1.7 million Americans annually, causing the death of 270,000 patients and 30 percent of all hospital deaths. To better understand the molecular mechanisms of sepsis to develop treatments, The Feinstein Institutes for Medical Research has been awarded a five-year, $2.5 million grant from the National Institutes of Health (NIH).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005250/en/

Dr. Ping Wang, MD (left) professor and chief scientific officer at the Feinstein Institutes will lead the new sepsis research. (Credit: Feinstein Institutes)

Dr. Ping Wang, MD (left) professor and chief scientific officer at the Feinstein Institutes will lead the new sepsis research. (Credit: Feinstein Institutes)

Sepsis occurs when the body’s immune system triggers inflammation in the body to help fight infection. However, this can cause damage to multiple organ systems, leading them to fail. Building off a previously awarded Maximizing Investigators' Research Award (MIRA) NIH grant, the research led by Ping Wang, MD, professor and chief scientific officer at the Feinstein Institutes, will further investigate extracellular cold inducible RNA-binding protein (eCIRP), which the team discovered as a new damage-associated molecular pattern molecule released in sepsis. The team will look at how neutrophils, a type of white blood cell that helps the body fight infection, and how it interacts with eCIRP.

“There is no standard of care therapies to prevent or treat sepsis and septic shock, an unfortunate complication that leads to unnecessary death,” said Dr. Wang. “With the continued support of the NIH we will be able to discover further the underlying mechanisms that trigger sepsis that may ultimately lead to new drugs and treatment.”

The MIRA grants provide investigators with greater stability and flexibility in their research, enhancing scientific productivity and the chances for significant breakthroughs. Dr. Wang and Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, were each awarded a MIRA grant in 2016. Dr. Wang’s received $2.4 million, which helped set the groundwork for this continued research.

“Low levels of inflammation are a crucial part of the body’s immune response, but too much of it can cause sepsis leading to widespread damage in the lungs, kidneys and others organs,” said Dr. Tracey. “Dr. Wang’s research, with support from the NIH, will allow us to better understand exactly what can initiate dangerous inflammation and how to treat the condition."

The Feinstein Institutes continues to lead in sepsis and septic shock research. Most recently, Haichao Wang, PhD, earned the Shock Society’s 2021 Scientific Achievement Award. Dr. Ping Wang received the same recognition in 2019.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.